This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
← catalyst calendarNCT07290803 · readout in 2,721 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
79
Countries
Canada, China, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-17 | actual | When the study began enrolling |
| Primary completion | 2034-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Utilizing Atopic Dermatitis (AD) Treatment
measured Baseline to up to 60 months
Duration of Treatment
measured Baseline to up to 60 months
AD Treatment Sequences
measured Baseline to up to 60 months
Number of Participants Initiating AD Treatments with Reasons
measured Baseline to up to 60 months
Number of Participants Interrupting AD Treatment
measured Baseline to up to 60 months
Number of Participants Discontinuing AD Treatment
measured Baseline to up to 60 months
Number of Participants Switching AD Treatments
measured Baseline to up to 60 months
Number of Participants Augmenting AD treatment
measured Baseline to up to 60 months
Number of Participants Modifying AD Treatment Dose
measured Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Eczema Area and Severity Index (EASI)
measured Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Body Surface Area (BSA)
measured Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD)
measured Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Revised Investigator's Global Assessment for Atopic Dermatitis (rIGA-AD)
measured Baseline to up to 60 months
Change in Atopic Dermatitis Control Test (ADCT) from Baseline
measured Baseline to up to 60 months
Change in Patient Global Impression of Severity (PGIS) from Baseline
measured Baseline to up to 60 months
Change in Itch severity as Measured with the Peak Pruritus Numeric Rating Scale (PP-NRS) from Baseline
measured Baseline to up to 60 months
Change in Skin Pain as Measured with Skin Pain Numeric Rating Scale (SP-NRS) from Baseline
measured Baseline to up to 60 months
Change in Sleep Disturbance as Measured with Sleep Disturbance Numeric Rating Scale (SD-NRS) from Baseline
measured Baseline to up to 60 months
Remission of AD
measured Baseline to up to 60 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed